nodes	percent_of_prediction	percent_of_DWPC	metapath
Tamoxifen—CYP19A1—polycystic ovary syndrome	0.343	0.576	CbGaD
Tamoxifen—CYP1A1—polycystic ovary syndrome	0.252	0.424	CbGaD
Tamoxifen—CYP19A1—follicular fluid—polycystic ovary syndrome	0.0151	0.0935	CbGeAlD
Tamoxifen—CYP19A1—corpus luteum—polycystic ovary syndrome	0.00871	0.0539	CbGeAlD
Tamoxifen—ESR2—ovarian follicle—polycystic ovary syndrome	0.00865	0.0535	CbGeAlD
Tamoxifen—CYP19A1—ovarian follicle—polycystic ovary syndrome	0.00681	0.0421	CbGeAlD
Tamoxifen—ESR1—ovarian follicle—polycystic ovary syndrome	0.00592	0.0366	CbGeAlD
Tamoxifen—FMO3—urine—polycystic ovary syndrome	0.00529	0.0327	CbGeAlD
Tamoxifen—Appetite absent—Metformin—polycystic ovary syndrome	0.00269	0.0793	CcSEcCtD
Tamoxifen—CYP2C19—urine—polycystic ovary syndrome	0.00234	0.0145	CbGeAlD
Tamoxifen—EBPL—adipose tissue—polycystic ovary syndrome	0.00231	0.0143	CbGeAlD
Tamoxifen—EBP—uterus—polycystic ovary syndrome	0.00226	0.014	CbGeAlD
Tamoxifen—EBPL—adrenal gland—polycystic ovary syndrome	0.00207	0.0128	CbGeAlD
Tamoxifen—Nail disorder—Metformin—polycystic ovary syndrome	0.00207	0.0608	CcSEcCtD
Tamoxifen—Upset stomach—Metformin—polycystic ovary syndrome	0.00204	0.0602	CcSEcCtD
Tamoxifen—EBPL—female gonad—polycystic ovary syndrome	0.00193	0.0119	CbGeAlD
Tamoxifen—CYP1A2—urine—polycystic ovary syndrome	0.00191	0.0118	CbGeAlD
Tamoxifen—SULT1A1—pituitary gland—polycystic ovary syndrome	0.00184	0.0114	CbGeAlD
Tamoxifen—SULT1A1—adipose tissue—polycystic ovary syndrome	0.00184	0.0113	CbGeAlD
Tamoxifen—CYP2C9—urine—polycystic ovary syndrome	0.00181	0.0112	CbGeAlD
Tamoxifen—EBPL—endocrine gland—polycystic ovary syndrome	0.0018	0.0111	CbGeAlD
Tamoxifen—EBP—endocrine gland—polycystic ovary syndrome	0.00172	0.0106	CbGeAlD
Tamoxifen—CYP2E1—urine—polycystic ovary syndrome	0.00172	0.0106	CbGeAlD
Tamoxifen—SULT1A1—adrenal gland—polycystic ovary syndrome	0.00165	0.0102	CbGeAlD
Tamoxifen—DHCR7—adrenal cortex—polycystic ovary syndrome	0.00162	0.01	CbGeAlD
Tamoxifen—ESRRA—adrenal cortex—polycystic ovary syndrome	0.0016	0.00987	CbGeAlD
Tamoxifen—Contusion—Metformin—polycystic ovary syndrome	0.00154	0.0452	CcSEcCtD
Tamoxifen—SULT1A1—female gonad—polycystic ovary syndrome	0.00153	0.00949	CbGeAlD
Tamoxifen—SULT1A1—vagina—polycystic ovary syndrome	0.00153	0.00943	CbGeAlD
Tamoxifen—Accidental injury—Metformin—polycystic ovary syndrome	0.00151	0.0446	CcSEcCtD
Tamoxifen—FMO1—endometrium—polycystic ovary syndrome	0.00145	0.00895	CbGeAlD
Tamoxifen—SULT1A1—endocrine gland—polycystic ovary syndrome	0.00143	0.00882	CbGeAlD
Tamoxifen—ESRRA—endometrium—polycystic ovary syndrome	0.00143	0.00881	CbGeAlD
Tamoxifen—FMO3—adrenal cortex—polycystic ovary syndrome	0.0014	0.00867	CbGeAlD
Tamoxifen—CYP3A4—urine—polycystic ovary syndrome	0.00138	0.00855	CbGeAlD
Tamoxifen—CYP2D6—urine—polycystic ovary syndrome	0.00136	0.00841	CbGeAlD
Tamoxifen—ESRRA—uterus—polycystic ovary syndrome	0.00131	0.00812	CbGeAlD
Tamoxifen—DHCR7—pituitary gland—polycystic ovary syndrome	0.00131	0.0081	CbGeAlD
Tamoxifen—FMO1—pituitary gland—polycystic ovary syndrome	0.00131	0.0081	CbGeAlD
Tamoxifen—DHCR7—adipose tissue—polycystic ovary syndrome	0.00131	0.00807	CbGeAlD
Tamoxifen—FMO1—adipose tissue—polycystic ovary syndrome	0.00131	0.00807	CbGeAlD
Tamoxifen—ESRRA—pituitary gland—polycystic ovary syndrome	0.00129	0.00798	CbGeAlD
Tamoxifen—ESRRA—adipose tissue—polycystic ovary syndrome	0.00128	0.00794	CbGeAlD
Tamoxifen—UGT1A4—endocrine gland—polycystic ovary syndrome	0.00125	0.0077	CbGeAlD
Tamoxifen—Lightheadedness—Metformin—polycystic ovary syndrome	0.0012	0.0353	CcSEcCtD
Tamoxifen—DHCR7—adrenal gland—polycystic ovary syndrome	0.00117	0.00724	CbGeAlD
Tamoxifen—FMO1—adrenal gland—polycystic ovary syndrome	0.00117	0.00724	CbGeAlD
Tamoxifen—ESRRA—adrenal gland—polycystic ovary syndrome	0.00115	0.00713	CbGeAlD
Tamoxifen—FMO3—pituitary gland—polycystic ovary syndrome	0.00113	0.007	CbGeAlD
Tamoxifen—FMO3—adipose tissue—polycystic ovary syndrome	0.00113	0.00697	CbGeAlD
Tamoxifen—DHCR7—female gonad—polycystic ovary syndrome	0.00109	0.00675	CbGeAlD
Tamoxifen—FMO1—female gonad—polycystic ovary syndrome	0.00109	0.00675	CbGeAlD
Tamoxifen—DHCR7—vagina—polycystic ovary syndrome	0.00109	0.00671	CbGeAlD
Tamoxifen—FMO1—vagina—polycystic ovary syndrome	0.00109	0.00671	CbGeAlD
Tamoxifen—ESRRA—female gonad—polycystic ovary syndrome	0.00107	0.00664	CbGeAlD
Tamoxifen—ESRRA—vagina—polycystic ovary syndrome	0.00107	0.0066	CbGeAlD
Tamoxifen—Injury—Metformin—polycystic ovary syndrome	0.00106	0.0311	CcSEcCtD
Tamoxifen—DHCR7—endocrine gland—polycystic ovary syndrome	0.00102	0.00628	CbGeAlD
Tamoxifen—FMO1—endocrine gland—polycystic ovary syndrome	0.00102	0.00628	CbGeAlD
Tamoxifen—FMO3—adrenal gland—polycystic ovary syndrome	0.00101	0.00626	CbGeAlD
Tamoxifen—ESRRA—endocrine gland—polycystic ovary syndrome	0.000999	0.00618	CbGeAlD
Tamoxifen—FMO3—vagina—polycystic ovary syndrome	0.000938	0.0058	CbGeAlD
Tamoxifen—Liver function test abnormal—Metformin—polycystic ovary syndrome	0.000898	0.0264	CcSEcCtD
Tamoxifen—CES1—adipose tissue—polycystic ovary syndrome	0.000891	0.00551	CbGeAlD
Tamoxifen—ABCB11—endocrine gland—polycystic ovary syndrome	0.000887	0.00549	CbGeAlD
Tamoxifen—FMO3—endocrine gland—polycystic ovary syndrome	0.000877	0.00542	CbGeAlD
Tamoxifen—Cramp muscle—Metformin—polycystic ovary syndrome	0.000876	0.0258	CcSEcCtD
Tamoxifen—CYP3A7—endocrine gland—polycystic ovary syndrome	0.000868	0.00537	CbGeAlD
Tamoxifen—Loperamide—POMC—polycystic ovary syndrome	0.000864	0.127	CrCbGaD
Tamoxifen—ESR2—endometrium—polycystic ovary syndrome	0.000856	0.00529	CbGeAlD
Tamoxifen—Influenza—Metformin—polycystic ovary syndrome	0.000841	0.0247	CcSEcCtD
Tamoxifen—Pancreatitis—Metformin—polycystic ovary syndrome	0.000824	0.0243	CcSEcCtD
Tamoxifen—Angina pectoris—Metformin—polycystic ovary syndrome	0.000819	0.0241	CcSEcCtD
Tamoxifen—Abdominal discomfort—Metformin—polycystic ovary syndrome	0.000806	0.0237	CcSEcCtD
Tamoxifen—ESR1—embryo—polycystic ovary syndrome	0.000801	0.00495	CbGeAlD
Tamoxifen—CES1—adrenal gland—polycystic ovary syndrome	0.000799	0.00494	CbGeAlD
Tamoxifen—Clomifene—CYP11A1—polycystic ovary syndrome	0.000791	0.116	CrCbGaD
Tamoxifen—ESR2—uterus—polycystic ovary syndrome	0.000789	0.00487	CbGeAlD
Tamoxifen—Neutropenia—Metformin—polycystic ovary syndrome	0.000786	0.0231	CcSEcCtD
Tamoxifen—CYP2A6—adipose tissue—polycystic ovary syndrome	0.000775	0.00479	CbGeAlD
Tamoxifen—ESR2—pituitary gland—polycystic ovary syndrome	0.000774	0.00479	CbGeAlD
Tamoxifen—CES1—female gonad—polycystic ovary syndrome	0.000745	0.00461	CbGeAlD
Tamoxifen—SIGMAR1—adrenal cortex—polycystic ovary syndrome	0.000742	0.00459	CbGeAlD
Tamoxifen—CES1—endocrine gland—polycystic ovary syndrome	0.000693	0.00428	CbGeAlD
Tamoxifen—ESR2—adrenal gland—polycystic ovary syndrome	0.000692	0.00428	CbGeAlD
Tamoxifen—CYP19A1—endometrium—polycystic ovary syndrome	0.000674	0.00417	CbGeAlD
Tamoxifen—Hepatitis—Metformin—polycystic ovary syndrome	0.000673	0.0198	CcSEcCtD
Tamoxifen—Hypoaesthesia—Metformin—polycystic ovary syndrome	0.000669	0.0197	CcSEcCtD
Tamoxifen—SIGMAR1—endometrium—polycystic ovary syndrome	0.000663	0.0041	CbGeAlD
Tamoxifen—Oedema peripheral—Metformin—polycystic ovary syndrome	0.000663	0.0195	CcSEcCtD
Tamoxifen—ESR2—female gonad—polycystic ovary syndrome	0.000645	0.00399	CbGeAlD
Tamoxifen—CYP2A6—vagina—polycystic ovary syndrome	0.000644	0.00398	CbGeAlD
Tamoxifen—ESR2—vagina—polycystic ovary syndrome	0.000641	0.00396	CbGeAlD
Tamoxifen—Flushing—Metformin—polycystic ovary syndrome	0.000624	0.0184	CcSEcCtD
Tamoxifen—CYP19A1—uterus—polycystic ovary syndrome	0.000621	0.00384	CbGeAlD
Tamoxifen—SIGMAR1—uterus—polycystic ovary syndrome	0.000611	0.00378	CbGeAlD
Tamoxifen—CYP19A1—adipose tissue—polycystic ovary syndrome	0.000608	0.00376	CbGeAlD
Tamoxifen—SIGMAR1—pituitary gland—polycystic ovary syndrome	0.0006	0.00371	CbGeAlD
Tamoxifen—ESR2—endocrine gland—polycystic ovary syndrome	0.0006	0.00371	CbGeAlD
Tamoxifen—SIGMAR1—adipose tissue—polycystic ovary syndrome	0.000597	0.00369	CbGeAlD
Tamoxifen—Diethylstilbestrol—CYP19A1—polycystic ovary syndrome	0.000597	0.0878	CrCbGaD
Tamoxifen—ESR1—endometrium—polycystic ovary syndrome	0.000586	0.00362	CbGeAlD
Tamoxifen—Erythema—Metformin—polycystic ovary syndrome	0.000586	0.0172	CcSEcCtD
Tamoxifen—Phenoxybenzamine—ADRA1D—polycystic ovary syndrome	0.000582	0.0856	CrCbGaD
Tamoxifen—CYP1B1—uterus—polycystic ovary syndrome	0.000581	0.00359	CbGeAlD
Tamoxifen—Dysgeusia—Metformin—polycystic ovary syndrome	0.000574	0.0169	CcSEcCtD
Tamoxifen—CYP1B1—pituitary gland—polycystic ovary syndrome	0.00057	0.00353	CbGeAlD
Tamoxifen—CYP1B1—adipose tissue—polycystic ovary syndrome	0.000568	0.00351	CbGeAlD
Tamoxifen—Muscle spasms—Metformin—polycystic ovary syndrome	0.000563	0.0166	CcSEcCtD
Tamoxifen—CYP19A1—adrenal gland—polycystic ovary syndrome	0.000545	0.00337	CbGeAlD
Tamoxifen—ESR1—uterus—polycystic ovary syndrome	0.00054	0.00334	CbGeAlD
Tamoxifen—SIGMAR1—adrenal gland—polycystic ovary syndrome	0.000536	0.00331	CbGeAlD
Tamoxifen—ESR1—pituitary gland—polycystic ovary syndrome	0.00053	0.00328	CbGeAlD
Tamoxifen—ESR1—adipose tissue—polycystic ovary syndrome	0.000528	0.00327	CbGeAlD
Tamoxifen—ABCG2—adrenal cortex—polycystic ovary syndrome	0.000526	0.00325	CbGeAlD
Tamoxifen—ABCC2—adrenal gland—polycystic ovary syndrome	0.00052	0.00322	CbGeAlD
Tamoxifen—CYP1B1—adrenal gland—polycystic ovary syndrome	0.00051	0.00315	CbGeAlD
Tamoxifen—CYP19A1—female gonad—polycystic ovary syndrome	0.000508	0.00314	CbGeAlD
Tamoxifen—Hypertension—Metformin—polycystic ovary syndrome	0.000506	0.0149	CcSEcCtD
Tamoxifen—SIGMAR1—female gonad—polycystic ovary syndrome	0.0005	0.00309	CbGeAlD
Tamoxifen—Chest pain—Metformin—polycystic ovary syndrome	0.000499	0.0147	CcSEcCtD
Tamoxifen—Myalgia—Metformin—polycystic ovary syndrome	0.000499	0.0147	CcSEcCtD
Tamoxifen—SIGMAR1—vagina—polycystic ovary syndrome	0.000497	0.00307	CbGeAlD
Tamoxifen—Phenoxybenzamine—ADRA1B—polycystic ovary syndrome	0.000496	0.073	CrCbGaD
Tamoxifen—Discomfort—Metformin—polycystic ovary syndrome	0.000493	0.0145	CcSEcCtD
Tamoxifen—CYP2B6—adrenal cortex—polycystic ovary syndrome	0.000485	0.003	CbGeAlD
Tamoxifen—CYP2C8—endometrium—polycystic ovary syndrome	0.000483	0.00298	CbGeAlD
Tamoxifen—Oedema—Metformin—polycystic ovary syndrome	0.000478	0.0141	CcSEcCtD
Tamoxifen—CYP1B1—female gonad—polycystic ovary syndrome	0.000475	0.00294	CbGeAlD
Tamoxifen—Infection—Metformin—polycystic ovary syndrome	0.000475	0.014	CcSEcCtD
Tamoxifen—ESR1—adrenal gland—polycystic ovary syndrome	0.000474	0.00293	CbGeAlD
Tamoxifen—CYP19A1—endocrine gland—polycystic ovary syndrome	0.000473	0.00292	CbGeAlD
Tamoxifen—ABCG2—endometrium—polycystic ovary syndrome	0.000469	0.0029	CbGeAlD
Tamoxifen—Thrombocytopenia—Metformin—polycystic ovary syndrome	0.000468	0.0138	CcSEcCtD
Tamoxifen—Hyperhidrosis—Metformin—polycystic ovary syndrome	0.000462	0.0136	CcSEcCtD
Tamoxifen—Anorexia—Metformin—polycystic ovary syndrome	0.000456	0.0134	CcSEcCtD
Tamoxifen—ABCC2—endocrine gland—polycystic ovary syndrome	0.000451	0.00279	CbGeAlD
Tamoxifen—CYP1B1—endocrine gland—polycystic ovary syndrome	0.000442	0.00273	CbGeAlD
Tamoxifen—ESR1—female gonad—polycystic ovary syndrome	0.000442	0.00273	CbGeAlD
Tamoxifen—ESR1—vagina—polycystic ovary syndrome	0.000439	0.00271	CbGeAlD
Tamoxifen—CYP2C8—pituitary gland—polycystic ovary syndrome	0.000437	0.0027	CbGeAlD
Tamoxifen—Musculoskeletal discomfort—Metformin—polycystic ovary syndrome	0.000435	0.0128	CcSEcCtD
Tamoxifen—ABCG2—uterus—polycystic ovary syndrome	0.000433	0.00267	CbGeAlD
Tamoxifen—Paraesthesia—Metformin—polycystic ovary syndrome	0.000429	0.0126	CcSEcCtD
Tamoxifen—Dyspnoea—Metformin—polycystic ovary syndrome	0.000426	0.0125	CcSEcCtD
Tamoxifen—ABCG2—pituitary gland—polycystic ovary syndrome	0.000425	0.00263	CbGeAlD
Tamoxifen—ABCG2—adipose tissue—polycystic ovary syndrome	0.000423	0.00262	CbGeAlD
Tamoxifen—Dyspepsia—Metformin—polycystic ovary syndrome	0.000421	0.0124	CcSEcCtD
Tamoxifen—Promazine—ADRA1D—polycystic ovary syndrome	0.000421	0.0619	CrCbGaD
Tamoxifen—Decreased appetite—Metformin—polycystic ovary syndrome	0.000416	0.0122	CcSEcCtD
Tamoxifen—CYP2C19—vagina—polycystic ovary syndrome	0.000414	0.00256	CbGeAlD
Tamoxifen—Gastrointestinal disorder—Metformin—polycystic ovary syndrome	0.000413	0.0121	CcSEcCtD
Tamoxifen—Fatigue—Metformin—polycystic ovary syndrome	0.000412	0.0121	CcSEcCtD
Tamoxifen—ESR1—endocrine gland—polycystic ovary syndrome	0.000411	0.00254	CbGeAlD
Tamoxifen—CYP1A1—uterus—polycystic ovary syndrome	0.000411	0.00254	CbGeAlD
Tamoxifen—Clomifene—CYP19A1—polycystic ovary syndrome	0.000409	0.0602	CrCbGaD
Tamoxifen—Constipation—Metformin—polycystic ovary syndrome	0.000409	0.012	CcSEcCtD
Tamoxifen—CYP1A1—adipose tissue—polycystic ovary syndrome	0.000402	0.00248	CbGeAlD
Tamoxifen—CYP3A5—adipose tissue—polycystic ovary syndrome	0.000393	0.00243	CbGeAlD
Tamoxifen—Gastrointestinal pain—Metformin—polycystic ovary syndrome	0.000391	0.0115	CcSEcCtD
Tamoxifen—CYP2C19—endocrine gland—polycystic ovary syndrome	0.000388	0.0024	CbGeAlD
Tamoxifen—Urticaria—Metformin—polycystic ovary syndrome	0.00038	0.0112	CcSEcCtD
Tamoxifen—ABCG2—adrenal gland—polycystic ovary syndrome	0.000379	0.00235	CbGeAlD
Tamoxifen—Abdominal pain—Metformin—polycystic ovary syndrome	0.000378	0.0111	CcSEcCtD
Tamoxifen—CYP2C8—vagina—polycystic ovary syndrome	0.000362	0.00224	CbGeAlD
Tamoxifen—Promazine—ADRA1B—polycystic ovary syndrome	0.000359	0.0528	CrCbGaD
Tamoxifen—ABCG2—female gonad—polycystic ovary syndrome	0.000354	0.00219	CbGeAlD
Tamoxifen—ABCG2—vagina—polycystic ovary syndrome	0.000352	0.00217	CbGeAlD
Tamoxifen—CYP2B6—adrenal gland—polycystic ovary syndrome	0.00035	0.00216	CbGeAlD
Tamoxifen—Benzphetamine—ADRA1A—polycystic ovary syndrome	0.00035	0.0514	CrCbGaD
Tamoxifen—Toremifene—CYP1A1—polycystic ovary syndrome	0.000348	0.0512	CrCbGaD
Tamoxifen—Asthenia—Metformin—polycystic ovary syndrome	0.000343	0.0101	CcSEcCtD
Tamoxifen—CYP2C8—endocrine gland—polycystic ovary syndrome	0.000338	0.00209	CbGeAlD
Tamoxifen—Pruritus—Metformin—polycystic ovary syndrome	0.000338	0.00996	CcSEcCtD
Tamoxifen—CYP1A1—female gonad—polycystic ovary syndrome	0.000336	0.00208	CbGeAlD
Tamoxifen—Phenoxybenzamine—ADRA1A—polycystic ovary syndrome	0.000334	0.0491	CrCbGaD
Tamoxifen—CYP1A1—vagina—polycystic ovary syndrome	0.000334	0.00206	CbGeAlD
Tamoxifen—CYP2E1—adrenal gland—polycystic ovary syndrome	0.000329	0.00203	CbGeAlD
Tamoxifen—CYP3A5—female gonad—polycystic ovary syndrome	0.000328	0.00203	CbGeAlD
Tamoxifen—Diarrhoea—Metformin—polycystic ovary syndrome	0.000327	0.00963	CcSEcCtD
Tamoxifen—CYP3A5—vagina—polycystic ovary syndrome	0.000326	0.00202	CbGeAlD
Tamoxifen—CYP2B6—vagina—polycystic ovary syndrome	0.000324	0.00201	CbGeAlD
Tamoxifen—Levomethadyl Acetate—CYP19A1—polycystic ovary syndrome	0.00032	0.047	CrCbGaD
Tamoxifen—CYP1A2—endocrine gland—polycystic ovary syndrome	0.000317	0.00196	CbGeAlD
Tamoxifen—ABCB1—embryo—polycystic ovary syndrome	0.000316	0.00196	CbGeAlD
Tamoxifen—Dizziness—Metformin—polycystic ovary syndrome	0.000316	0.00931	CcSEcCtD
Tamoxifen—CYP1A1—endocrine gland—polycystic ovary syndrome	0.000312	0.00193	CbGeAlD
Tamoxifen—CYP3A5—endocrine gland—polycystic ovary syndrome	0.000305	0.00189	CbGeAlD
Tamoxifen—Vomiting—Metformin—polycystic ovary syndrome	0.000304	0.00895	CcSEcCtD
Tamoxifen—CYP2B6—endocrine gland—polycystic ovary syndrome	0.000304	0.00188	CbGeAlD
Tamoxifen—Rash—Metformin—polycystic ovary syndrome	0.000301	0.00887	CcSEcCtD
Tamoxifen—Dermatitis—Metformin—polycystic ovary syndrome	0.000301	0.00886	CcSEcCtD
Tamoxifen—Clomifene—CYP1A1—polycystic ovary syndrome	0.000301	0.0443	CrCbGaD
Tamoxifen—CYP2C9—endocrine gland—polycystic ovary syndrome	0.000301	0.00186	CbGeAlD
Tamoxifen—Headache—Metformin—polycystic ovary syndrome	0.000299	0.00882	CcSEcCtD
Tamoxifen—CYP2E1—endocrine gland—polycystic ovary syndrome	0.000285	0.00176	CbGeAlD
Tamoxifen—Nausea—Metformin—polycystic ovary syndrome	0.000284	0.00836	CcSEcCtD
Tamoxifen—ABCB1—adrenal cortex—polycystic ovary syndrome	0.000259	0.0016	CbGeAlD
Tamoxifen—CYP2D6—female gonad—polycystic ovary syndrome	0.000243	0.0015	CbGeAlD
Tamoxifen—Promazine—ADRA1A—polycystic ovary syndrome	0.000242	0.0355	CrCbGaD
Tamoxifen—ABCB1—endometrium—polycystic ovary syndrome	0.000231	0.00143	CbGeAlD
Tamoxifen—CYP3A4—endocrine gland—polycystic ovary syndrome	0.000229	0.00142	CbGeAlD
Tamoxifen—CYP2D6—endocrine gland—polycystic ovary syndrome	0.000226	0.00139	CbGeAlD
Tamoxifen—ABCB1—uterus—polycystic ovary syndrome	0.000213	0.00132	CbGeAlD
Tamoxifen—ABCB1—pituitary gland—polycystic ovary syndrome	0.000209	0.00129	CbGeAlD
Tamoxifen—ABCB1—adipose tissue—polycystic ovary syndrome	0.000209	0.00129	CbGeAlD
Tamoxifen—Phenoxybenzamine—ADRB2—polycystic ovary syndrome	0.000199	0.0292	CrCbGaD
Tamoxifen—Methadone—CYP19A1—polycystic ovary syndrome	0.000187	0.0276	CrCbGaD
Tamoxifen—ABCB1—adrenal gland—polycystic ovary syndrome	0.000187	0.00116	CbGeAlD
Tamoxifen—ABCB1—female gonad—polycystic ovary syndrome	0.000174	0.00108	CbGeAlD
Tamoxifen—ABCB1—vagina—polycystic ovary syndrome	0.000173	0.00107	CbGeAlD
Tamoxifen—ABCB1—endocrine gland—polycystic ovary syndrome	0.000162	0.001	CbGeAlD
Tamoxifen—CYP2C19—Metabolism—AKR1C1—polycystic ovary syndrome	8.97e-06	4.44e-05	CbGpPWpGaD
Tamoxifen—CYP2C8—Metabolism—RRM2—polycystic ovary syndrome	8.96e-06	4.44e-05	CbGpPWpGaD
Tamoxifen—ABCB11—Metabolism—PPARG—polycystic ovary syndrome	8.95e-06	4.43e-05	CbGpPWpGaD
Tamoxifen—CYP2E1—Metabolism—AKR1C3—polycystic ovary syndrome	8.95e-06	4.43e-05	CbGpPWpGaD
Tamoxifen—CYP1A1—Metabolism—CYP11A1—polycystic ovary syndrome	8.94e-06	4.43e-05	CbGpPWpGaD
Tamoxifen—CYP19A1—Metabolism—CYP1A1—polycystic ovary syndrome	8.94e-06	4.43e-05	CbGpPWpGaD
Tamoxifen—CYP3A5—Metabolism—AKR1C3—polycystic ovary syndrome	8.93e-06	4.42e-05	CbGpPWpGaD
Tamoxifen—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—polycystic ovary syndrome	8.88e-06	4.4e-05	CbGpPWpGaD
Tamoxifen—CYP1A1—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	8.87e-06	4.39e-05	CbGpPWpGaD
Tamoxifen—ABCB11—Metabolism—POMC—polycystic ovary syndrome	8.83e-06	4.37e-05	CbGpPWpGaD
Tamoxifen—CYP2A6—Metabolism—CYP19A1—polycystic ovary syndrome	8.82e-06	4.37e-05	CbGpPWpGaD
Tamoxifen—CYP2E1—Metabolism—CYP17A1—polycystic ovary syndrome	8.81e-06	4.36e-05	CbGpPWpGaD
Tamoxifen—CYP3A5—Metabolism—CYP17A1—polycystic ovary syndrome	8.79e-06	4.35e-05	CbGpPWpGaD
Tamoxifen—ABCB11—Metabolism—INS—polycystic ovary syndrome	8.78e-06	4.35e-05	CbGpPWpGaD
Tamoxifen—ABCB1—Metabolism—AKR1C1—polycystic ovary syndrome	8.76e-06	4.34e-05	CbGpPWpGaD
Tamoxifen—CYP2D6—Metabolism—LHB—polycystic ovary syndrome	8.72e-06	4.32e-05	CbGpPWpGaD
Tamoxifen—ABCG2—Metabolism—GNAS—polycystic ovary syndrome	8.67e-06	4.29e-05	CbGpPWpGaD
Tamoxifen—CYP2C9—Metabolism—LHB—polycystic ovary syndrome	8.64e-06	4.28e-05	CbGpPWpGaD
Tamoxifen—CYP2C8—Metabolism—YAP1—polycystic ovary syndrome	8.64e-06	4.28e-05	CbGpPWpGaD
Tamoxifen—CYP1B1—Metabolism—CYP1A1—polycystic ovary syndrome	8.61e-06	4.26e-05	CbGpPWpGaD
Tamoxifen—CYP3A7—Metabolism—GNAS—polycystic ovary syndrome	8.59e-06	4.26e-05	CbGpPWpGaD
Tamoxifen—CYP2D6—Metabolism—HSD3B2—polycystic ovary syndrome	8.52e-06	4.22e-05	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—NGFR—polycystic ovary syndrome	8.5e-06	4.21e-05	CbGpPWpGaD
Tamoxifen—CYP1A2—Metabolism—HMMR—polycystic ovary syndrome	8.49e-06	4.2e-05	CbGpPWpGaD
Tamoxifen—CYP2C9—Metabolism—HSD3B2—polycystic ovary syndrome	8.45e-06	4.18e-05	CbGpPWpGaD
Tamoxifen—CYP1A1—Metabolism—AKR1C3—polycystic ovary syndrome	8.44e-06	4.18e-05	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—PRL—polycystic ovary syndrome	8.42e-06	4.17e-05	CbGpPWpGaD
Tamoxifen—CYP19A1—Metabolism—MTHFR—polycystic ovary syndrome	8.33e-06	4.13e-05	CbGpPWpGaD
Tamoxifen—CYP1A1—Metabolism—CYP17A1—polycystic ovary syndrome	8.31e-06	4.11e-05	CbGpPWpGaD
Tamoxifen—CYP2C8—Metabolism—NAMPT—polycystic ovary syndrome	8.3e-06	4.11e-05	CbGpPWpGaD
Tamoxifen—ABCG2—Metabolism—NCOR1—polycystic ovary syndrome	8.26e-06	4.09e-05	CbGpPWpGaD
Tamoxifen—CYP2C19—Metabolism—SULT2A1—polycystic ovary syndrome	8.26e-06	4.09e-05	CbGpPWpGaD
Tamoxifen—CYP2D6—Metabolism—AKR1C1—polycystic ovary syndrome	8.25e-06	4.09e-05	CbGpPWpGaD
Tamoxifen—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	8.25e-06	4.08e-05	CbGpPWpGaD
Tamoxifen—CYP2C8—Metabolism—CYP11A1—polycystic ovary syndrome	8.19e-06	4.06e-05	CbGpPWpGaD
Tamoxifen—CYP3A7—Metabolism—NCOR1—polycystic ovary syndrome	8.19e-06	4.05e-05	CbGpPWpGaD
Tamoxifen—CYP2C9—Metabolism—AKR1C1—polycystic ovary syndrome	8.18e-06	4.05e-05	CbGpPWpGaD
Tamoxifen—CYP2C8—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	8.13e-06	4.03e-05	CbGpPWpGaD
Tamoxifen—CYP3A4—Metabolism—PNPLA2—polycystic ovary syndrome	8.13e-06	4.02e-05	CbGpPWpGaD
Tamoxifen—CYP1A2—Metabolism—HSD3B1—polycystic ovary syndrome	8.1e-06	4.01e-05	CbGpPWpGaD
Tamoxifen—ABCB1—Metabolism—SULT2A1—polycystic ovary syndrome	8.06e-06	3.99e-05	CbGpPWpGaD
Tamoxifen—CYP1B1—Metabolism—MTHFR—polycystic ovary syndrome	8.02e-06	3.97e-05	CbGpPWpGaD
Tamoxifen—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—polycystic ovary syndrome	8e-06	3.96e-05	CbGpPWpGaD
Tamoxifen—CYP2C19—Metabolism—RRM2—polycystic ovary syndrome	8e-06	3.96e-05	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—ADRB2—polycystic ovary syndrome	7.99e-06	3.96e-05	CbGpPWpGaD
Tamoxifen—CYP2A6—Metabolism—GNAS—polycystic ovary syndrome	7.88e-06	3.9e-05	CbGpPWpGaD
Tamoxifen—ABCG2—Metabolism—CYP1A1—polycystic ovary syndrome	7.83e-06	3.88e-05	CbGpPWpGaD
Tamoxifen—ABCB1—Metabolism—RRM2—polycystic ovary syndrome	7.8e-06	3.86e-05	CbGpPWpGaD
Tamoxifen—CYP2B6—Metabolism—TH—polycystic ovary syndrome	7.78e-06	3.85e-05	CbGpPWpGaD
Tamoxifen—ESR1—Gene Expression—PPARG—polycystic ovary syndrome	7.78e-06	3.85e-05	CbGpPWpGaD
Tamoxifen—CYP3A7—Metabolism—CYP1A1—polycystic ovary syndrome	7.76e-06	3.84e-05	CbGpPWpGaD
Tamoxifen—CYP2C8—Metabolism—AKR1C3—polycystic ovary syndrome	7.74e-06	3.83e-05	CbGpPWpGaD
Tamoxifen—CYP2C19—Metabolism—YAP1—polycystic ovary syndrome	7.71e-06	3.82e-05	CbGpPWpGaD
Tamoxifen—CYP3A4—Metabolism—SRD5A1—polycystic ovary syndrome	7.7e-06	3.81e-05	CbGpPWpGaD
Tamoxifen—CYP2E1—Metabolism—TH—polycystic ovary syndrome	7.62e-06	3.78e-05	CbGpPWpGaD
Tamoxifen—CYP2C8—Metabolism—CYP17A1—polycystic ovary syndrome	7.62e-06	3.77e-05	CbGpPWpGaD
Tamoxifen—CYP3A5—Metabolism—TH—polycystic ovary syndrome	7.61e-06	3.77e-05	CbGpPWpGaD
Tamoxifen—CYP2D6—Metabolism—SULT2A1—polycystic ovary syndrome	7.59e-06	3.76e-05	CbGpPWpGaD
Tamoxifen—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—polycystic ovary syndrome	7.59e-06	3.76e-05	CbGpPWpGaD
Tamoxifen—CYP2B6—Metabolism—SLC2A4—polycystic ovary syndrome	7.57e-06	3.75e-05	CbGpPWpGaD
Tamoxifen—CYP2C9—Metabolism—SULT2A1—polycystic ovary syndrome	7.53e-06	3.73e-05	CbGpPWpGaD
Tamoxifen—ABCB1—Metabolism—YAP1—polycystic ovary syndrome	7.52e-06	3.73e-05	CbGpPWpGaD
Tamoxifen—CYP2A6—Metabolism—NCOR1—polycystic ovary syndrome	7.5e-06	3.72e-05	CbGpPWpGaD
Tamoxifen—CYP2E1—Metabolism—SLC2A4—polycystic ovary syndrome	7.42e-06	3.67e-05	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—GNAS—polycystic ovary syndrome	7.41e-06	3.67e-05	CbGpPWpGaD
Tamoxifen—CYP2C19—Metabolism—NAMPT—polycystic ovary syndrome	7.41e-06	3.67e-05	CbGpPWpGaD
Tamoxifen—CYP3A5—Metabolism—SLC2A4—polycystic ovary syndrome	7.4e-06	3.67e-05	CbGpPWpGaD
Tamoxifen—CYP1A2—Metabolism—LHB—polycystic ovary syndrome	7.38e-06	3.66e-05	CbGpPWpGaD
Tamoxifen—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	7.36e-06	3.65e-05	CbGpPWpGaD
Tamoxifen—CYP2D6—Metabolism—RRM2—polycystic ovary syndrome	7.35e-06	3.64e-05	CbGpPWpGaD
Tamoxifen—CYP3A4—Metabolism—STAR—polycystic ovary syndrome	7.35e-06	3.64e-05	CbGpPWpGaD
Tamoxifen—CYP2C19—Metabolism—CYP11A1—polycystic ovary syndrome	7.31e-06	3.62e-05	CbGpPWpGaD
Tamoxifen—ABCG2—Metabolism—MTHFR—polycystic ovary syndrome	7.3e-06	3.61e-05	CbGpPWpGaD
Tamoxifen—CYP2C9—Metabolism—RRM2—polycystic ovary syndrome	7.29e-06	3.61e-05	CbGpPWpGaD
Tamoxifen—CYP2C19—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	7.26e-06	3.6e-05	CbGpPWpGaD
Tamoxifen—CYP3A7—Metabolism—MTHFR—polycystic ovary syndrome	7.23e-06	3.58e-05	CbGpPWpGaD
Tamoxifen—ABCB1—Metabolism—NAMPT—polycystic ovary syndrome	7.23e-06	3.58e-05	CbGpPWpGaD
Tamoxifen—CYP1A2—Metabolism—HSD3B2—polycystic ovary syndrome	7.22e-06	3.57e-05	CbGpPWpGaD
Tamoxifen—CYP1A1—Metabolism—TH—polycystic ovary syndrome	7.19e-06	3.56e-05	CbGpPWpGaD
Tamoxifen—ABCB1—Metabolism—CYP11A1—polycystic ovary syndrome	7.14e-06	3.53e-05	CbGpPWpGaD
Tamoxifen—CYP2B6—Metabolism—CYP19A1—polycystic ovary syndrome	7.12e-06	3.53e-05	CbGpPWpGaD
Tamoxifen—CYP2A6—Metabolism—CYP1A1—polycystic ovary syndrome	7.11e-06	3.52e-05	CbGpPWpGaD
Tamoxifen—CYP2D6—Metabolism—YAP1—polycystic ovary syndrome	7.09e-06	3.51e-05	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—NCOR1—polycystic ovary syndrome	7.06e-06	3.49e-05	CbGpPWpGaD
Tamoxifen—CYP2C9—Metabolism—YAP1—polycystic ovary syndrome	7.03e-06	3.48e-05	CbGpPWpGaD
Tamoxifen—ESR1—Gene Expression—SERPINE1—polycystic ovary syndrome	7.01e-06	3.47e-05	CbGpPWpGaD
Tamoxifen—CYP1A1—Metabolism—SLC2A4—polycystic ovary syndrome	6.99e-06	3.46e-05	CbGpPWpGaD
Tamoxifen—CYP1A2—Metabolism—AKR1C1—polycystic ovary syndrome	6.99e-06	3.46e-05	CbGpPWpGaD
Tamoxifen—CYP2E1—Metabolism—CYP19A1—polycystic ovary syndrome	6.97e-06	3.45e-05	CbGpPWpGaD
Tamoxifen—CYP3A5—Metabolism—CYP19A1—polycystic ovary syndrome	6.96e-06	3.45e-05	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—NRG1—polycystic ovary syndrome	6.93e-06	3.43e-05	CbGpPWpGaD
Tamoxifen—CYP2C19—Metabolism—AKR1C3—polycystic ovary syndrome	6.91e-06	3.42e-05	CbGpPWpGaD
Tamoxifen—CYP2D6—Metabolism—NAMPT—polycystic ovary syndrome	6.81e-06	3.37e-05	CbGpPWpGaD
Tamoxifen—CYP2C19—Metabolism—CYP17A1—polycystic ovary syndrome	6.8e-06	3.37e-05	CbGpPWpGaD
Tamoxifen—CYP19A1—Metabolism—PPARG—polycystic ovary syndrome	6.76e-06	3.35e-05	CbGpPWpGaD
Tamoxifen—CYP2C9—Metabolism—NAMPT—polycystic ovary syndrome	6.75e-06	3.34e-05	CbGpPWpGaD
Tamoxifen—ABCB1—Metabolism—AKR1C3—polycystic ovary syndrome	6.74e-06	3.34e-05	CbGpPWpGaD
Tamoxifen—CYP2D6—Metabolism—CYP11A1—polycystic ovary syndrome	6.73e-06	3.33e-05	CbGpPWpGaD
Tamoxifen—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	6.71e-06	3.32e-05	CbGpPWpGaD
Tamoxifen—CYP2C9—Metabolism—CYP11A1—polycystic ovary syndrome	6.67e-06	3.3e-05	CbGpPWpGaD
Tamoxifen—CYP19A1—Metabolism—POMC—polycystic ovary syndrome	6.66e-06	3.3e-05	CbGpPWpGaD
Tamoxifen—ABCB1—Metabolism—CYP17A1—polycystic ovary syndrome	6.64e-06	3.29e-05	CbGpPWpGaD
Tamoxifen—CYP2A6—Metabolism—MTHFR—polycystic ovary syndrome	6.63e-06	3.28e-05	CbGpPWpGaD
Tamoxifen—CYP19A1—Metabolism—INS—polycystic ovary syndrome	6.63e-06	3.28e-05	CbGpPWpGaD
Tamoxifen—CYP2C9—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	6.62e-06	3.28e-05	CbGpPWpGaD
Tamoxifen—CYP2C8—Metabolism—TH—polycystic ovary syndrome	6.59e-06	3.26e-05	CbGpPWpGaD
Tamoxifen—CYP1A1—Metabolism—CYP19A1—polycystic ovary syndrome	6.58e-06	3.26e-05	CbGpPWpGaD
Tamoxifen—CYP3A4—Metabolism—HMMR—polycystic ovary syndrome	6.55e-06	3.24e-05	CbGpPWpGaD
Tamoxifen—CYP1B1—Metabolism—PPARG—polycystic ovary syndrome	6.51e-06	3.22e-05	CbGpPWpGaD
Tamoxifen—CYP1A2—Metabolism—SULT2A1—polycystic ovary syndrome	6.43e-06	3.19e-05	CbGpPWpGaD
Tamoxifen—CYP1B1—Metabolism—POMC—polycystic ovary syndrome	6.42e-06	3.18e-05	CbGpPWpGaD
Tamoxifen—CYP2C8—Metabolism—SLC2A4—polycystic ovary syndrome	6.41e-06	3.17e-05	CbGpPWpGaD
Tamoxifen—CYP1B1—Metabolism—INS—polycystic ovary syndrome	6.38e-06	3.16e-05	CbGpPWpGaD
Tamoxifen—CYP2B6—Metabolism—GNAS—polycystic ovary syndrome	6.36e-06	3.15e-05	CbGpPWpGaD
Tamoxifen—CYP2D6—Metabolism—AKR1C3—polycystic ovary syndrome	6.35e-06	3.15e-05	CbGpPWpGaD
Tamoxifen—CYP2C9—Metabolism—AKR1C3—polycystic ovary syndrome	6.3e-06	3.12e-05	CbGpPWpGaD
Tamoxifen—CYP2D6—Metabolism—CYP17A1—polycystic ovary syndrome	6.25e-06	3.1e-05	CbGpPWpGaD
Tamoxifen—CYP3A4—Metabolism—HSD3B1—polycystic ovary syndrome	6.25e-06	3.09e-05	CbGpPWpGaD
Tamoxifen—CYP1A2—Metabolism—RRM2—polycystic ovary syndrome	6.23e-06	3.08e-05	CbGpPWpGaD
Tamoxifen—CYP2E1—Metabolism—GNAS—polycystic ovary syndrome	6.22e-06	3.08e-05	CbGpPWpGaD
Tamoxifen—CYP3A5—Metabolism—GNAS—polycystic ovary syndrome	6.21e-06	3.08e-05	CbGpPWpGaD
Tamoxifen—CYP2C9—Metabolism—CYP17A1—polycystic ovary syndrome	6.2e-06	3.07e-05	CbGpPWpGaD
Tamoxifen—CYP2B6—Metabolism—NCOR1—polycystic ovary syndrome	6.05e-06	3e-05	CbGpPWpGaD
Tamoxifen—CYP2C8—Metabolism—CYP19A1—polycystic ovary syndrome	6.03e-06	2.98e-05	CbGpPWpGaD
Tamoxifen—CYP1A2—Metabolism—YAP1—polycystic ovary syndrome	6.01e-06	2.97e-05	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—IRS2—polycystic ovary syndrome	5.93e-06	2.94e-05	CbGpPWpGaD
Tamoxifen—CYP2E1—Metabolism—NCOR1—polycystic ovary syndrome	5.93e-06	2.94e-05	CbGpPWpGaD
Tamoxifen—ABCG2—Metabolism—PPARG—polycystic ovary syndrome	5.92e-06	2.93e-05	CbGpPWpGaD
Tamoxifen—CYP3A5—Metabolism—NCOR1—polycystic ovary syndrome	5.92e-06	2.93e-05	CbGpPWpGaD
Tamoxifen—CYP2C19—Metabolism—TH—polycystic ovary syndrome	5.88e-06	2.91e-05	CbGpPWpGaD
Tamoxifen—CYP1A1—Metabolism—GNAS—polycystic ovary syndrome	5.87e-06	2.91e-05	CbGpPWpGaD
Tamoxifen—CYP3A7—Metabolism—PPARG—polycystic ovary syndrome	5.87e-06	2.9e-05	CbGpPWpGaD
Tamoxifen—ABCG2—Metabolism—POMC—polycystic ovary syndrome	5.84e-06	2.89e-05	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—LEP—polycystic ovary syndrome	5.81e-06	2.87e-05	CbGpPWpGaD
Tamoxifen—ABCG2—Metabolism—INS—polycystic ovary syndrome	5.81e-06	2.87e-05	CbGpPWpGaD
Tamoxifen—CYP3A7—Metabolism—POMC—polycystic ovary syndrome	5.79e-06	2.87e-05	CbGpPWpGaD
Tamoxifen—CYP1A2—Metabolism—NAMPT—polycystic ovary syndrome	5.77e-06	2.86e-05	CbGpPWpGaD
Tamoxifen—CYP3A7—Metabolism—INS—polycystic ovary syndrome	5.75e-06	2.85e-05	CbGpPWpGaD
Tamoxifen—ABCB1—Metabolism—TH—polycystic ovary syndrome	5.74e-06	2.84e-05	CbGpPWpGaD
Tamoxifen—CYP2B6—Metabolism—CYP1A1—polycystic ovary syndrome	5.74e-06	2.84e-05	CbGpPWpGaD
Tamoxifen—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	5.74e-06	2.84e-05	CbGpPWpGaD
Tamoxifen—CYP2C19—Metabolism—SLC2A4—polycystic ovary syndrome	5.72e-06	2.83e-05	CbGpPWpGaD
Tamoxifen—CYP3A4—Metabolism—LHB—polycystic ovary syndrome	5.7e-06	2.82e-05	CbGpPWpGaD
Tamoxifen—CYP1A2—Metabolism—CYP11A1—polycystic ovary syndrome	5.7e-06	2.82e-05	CbGpPWpGaD
Tamoxifen—CYP1A2—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	5.66e-06	2.8e-05	CbGpPWpGaD
Tamoxifen—CYP2E1—Metabolism—CYP1A1—polycystic ovary syndrome	5.62e-06	2.78e-05	CbGpPWpGaD
Tamoxifen—CYP3A5—Metabolism—CYP1A1—polycystic ovary syndrome	5.61e-06	2.78e-05	CbGpPWpGaD
Tamoxifen—CYP1A1—Metabolism—NCOR1—polycystic ovary syndrome	5.59e-06	2.77e-05	CbGpPWpGaD
Tamoxifen—ABCB1—Metabolism—SLC2A4—polycystic ovary syndrome	5.59e-06	2.77e-05	CbGpPWpGaD
Tamoxifen—CYP3A4—Metabolism—HSD3B2—polycystic ovary syndrome	5.57e-06	2.76e-05	CbGpPWpGaD
Tamoxifen—CYP2D6—Metabolism—TH—polycystic ovary syndrome	5.41e-06	2.68e-05	CbGpPWpGaD
Tamoxifen—CYP3A4—Metabolism—AKR1C1—polycystic ovary syndrome	5.39e-06	2.67e-05	CbGpPWpGaD
Tamoxifen—CYP1A2—Metabolism—AKR1C3—polycystic ovary syndrome	5.38e-06	2.66e-05	CbGpPWpGaD
Tamoxifen—CYP2C19—Metabolism—CYP19A1—polycystic ovary syndrome	5.38e-06	2.66e-05	CbGpPWpGaD
Tamoxifen—CYP2C8—Metabolism—GNAS—polycystic ovary syndrome	5.38e-06	2.66e-05	CbGpPWpGaD
Tamoxifen—CYP2A6—Metabolism—PPARG—polycystic ovary syndrome	5.38e-06	2.66e-05	CbGpPWpGaD
Tamoxifen—CYP2C9—Metabolism—TH—polycystic ovary syndrome	5.36e-06	2.66e-05	CbGpPWpGaD
Tamoxifen—CYP2B6—Metabolism—MTHFR—polycystic ovary syndrome	5.35e-06	2.65e-05	CbGpPWpGaD
Tamoxifen—CYP2A6—Metabolism—POMC—polycystic ovary syndrome	5.3e-06	2.63e-05	CbGpPWpGaD
Tamoxifen—CYP1A2—Metabolism—CYP17A1—polycystic ovary syndrome	5.3e-06	2.62e-05	CbGpPWpGaD
Tamoxifen—CYP2A6—Metabolism—INS—polycystic ovary syndrome	5.27e-06	2.61e-05	CbGpPWpGaD
Tamoxifen—CYP2D6—Metabolism—SLC2A4—polycystic ovary syndrome	5.26e-06	2.61e-05	CbGpPWpGaD
Tamoxifen—ABCB1—Metabolism—CYP19A1—polycystic ovary syndrome	5.25e-06	2.6e-05	CbGpPWpGaD
Tamoxifen—CYP2E1—Metabolism—MTHFR—polycystic ovary syndrome	5.24e-06	2.59e-05	CbGpPWpGaD
Tamoxifen—CYP3A5—Metabolism—MTHFR—polycystic ovary syndrome	5.23e-06	2.59e-05	CbGpPWpGaD
Tamoxifen—CYP2C9—Metabolism—SLC2A4—polycystic ovary syndrome	5.22e-06	2.58e-05	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—IRS1—polycystic ovary syndrome	5.18e-06	2.56e-05	CbGpPWpGaD
Tamoxifen—CYP2C8—Metabolism—NCOR1—polycystic ovary syndrome	5.13e-06	2.54e-05	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—POMC—polycystic ovary syndrome	4.99e-06	2.47e-05	CbGpPWpGaD
Tamoxifen—CYP3A4—Metabolism—SULT2A1—polycystic ovary syndrome	4.96e-06	2.46e-05	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—INS—polycystic ovary syndrome	4.96e-06	2.46e-05	CbGpPWpGaD
Tamoxifen—CYP2D6—Metabolism—CYP19A1—polycystic ovary syndrome	4.95e-06	2.45e-05	CbGpPWpGaD
Tamoxifen—CYP1A1—Metabolism—MTHFR—polycystic ovary syndrome	4.94e-06	2.45e-05	CbGpPWpGaD
Tamoxifen—CYP2C9—Metabolism—CYP19A1—polycystic ovary syndrome	4.91e-06	2.43e-05	CbGpPWpGaD
Tamoxifen—CYP2C8—Metabolism—CYP1A1—polycystic ovary syndrome	4.86e-06	2.41e-05	CbGpPWpGaD
Tamoxifen—CYP3A4—Metabolism—RRM2—polycystic ovary syndrome	4.81e-06	2.38e-05	CbGpPWpGaD
Tamoxifen—CYP2C19—Metabolism—GNAS—polycystic ovary syndrome	4.8e-06	2.38e-05	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—IGF1—polycystic ovary syndrome	4.8e-06	2.38e-05	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—AKT2—polycystic ovary syndrome	4.79e-06	2.37e-05	CbGpPWpGaD
Tamoxifen—ABCB1—Metabolism—GNAS—polycystic ovary syndrome	4.69e-06	2.32e-05	CbGpPWpGaD
Tamoxifen—CYP3A4—Metabolism—YAP1—polycystic ovary syndrome	4.63e-06	2.29e-05	CbGpPWpGaD
Tamoxifen—CYP1A2—Metabolism—TH—polycystic ovary syndrome	4.58e-06	2.27e-05	CbGpPWpGaD
Tamoxifen—CYP2C19—Metabolism—NCOR1—polycystic ovary syndrome	4.57e-06	2.27e-05	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	4.56e-06	2.26e-05	CbGpPWpGaD
Tamoxifen—CYP2C8—Metabolism—MTHFR—polycystic ovary syndrome	4.53e-06	2.24e-05	CbGpPWpGaD
Tamoxifen—ABCB1—Metabolism—NCOR1—polycystic ovary syndrome	4.47e-06	2.21e-05	CbGpPWpGaD
Tamoxifen—CYP1A2—Metabolism—SLC2A4—polycystic ovary syndrome	4.46e-06	2.21e-05	CbGpPWpGaD
Tamoxifen—CYP3A4—Metabolism—NAMPT—polycystic ovary syndrome	4.45e-06	2.2e-05	CbGpPWpGaD
Tamoxifen—CYP2D6—Metabolism—GNAS—polycystic ovary syndrome	4.42e-06	2.19e-05	CbGpPWpGaD
Tamoxifen—CYP3A4—Metabolism—CYP11A1—polycystic ovary syndrome	4.4e-06	2.18e-05	CbGpPWpGaD
Tamoxifen—CYP2C9—Metabolism—GNAS—polycystic ovary syndrome	4.38e-06	2.17e-05	CbGpPWpGaD
Tamoxifen—CYP2B6—Metabolism—PPARG—polycystic ovary syndrome	4.34e-06	2.15e-05	CbGpPWpGaD
Tamoxifen—CYP2C19—Metabolism—CYP1A1—polycystic ovary syndrome	4.34e-06	2.15e-05	CbGpPWpGaD
Tamoxifen—CYP2B6—Metabolism—POMC—polycystic ovary syndrome	4.28e-06	2.12e-05	CbGpPWpGaD
Tamoxifen—CYP2B6—Metabolism—INS—polycystic ovary syndrome	4.26e-06	2.11e-05	CbGpPWpGaD
Tamoxifen—CYP2E1—Metabolism—PPARG—polycystic ovary syndrome	4.25e-06	2.1e-05	CbGpPWpGaD
Tamoxifen—CYP3A5—Metabolism—PPARG—polycystic ovary syndrome	4.24e-06	2.1e-05	CbGpPWpGaD
Tamoxifen—ABCB1—Metabolism—CYP1A1—polycystic ovary syndrome	4.23e-06	2.1e-05	CbGpPWpGaD
Tamoxifen—CYP2D6—Metabolism—NCOR1—polycystic ovary syndrome	4.21e-06	2.08e-05	CbGpPWpGaD
Tamoxifen—CYP1A2—Metabolism—CYP19A1—polycystic ovary syndrome	4.19e-06	2.08e-05	CbGpPWpGaD
Tamoxifen—CYP2E1—Metabolism—POMC—polycystic ovary syndrome	4.19e-06	2.08e-05	CbGpPWpGaD
Tamoxifen—CYP3A5—Metabolism—POMC—polycystic ovary syndrome	4.18e-06	2.07e-05	CbGpPWpGaD
Tamoxifen—CYP2C9—Metabolism—NCOR1—polycystic ovary syndrome	4.17e-06	2.07e-05	CbGpPWpGaD
Tamoxifen—CYP2E1—Metabolism—INS—polycystic ovary syndrome	4.17e-06	2.06e-05	CbGpPWpGaD
Tamoxifen—CYP3A5—Metabolism—INS—polycystic ovary syndrome	4.16e-06	2.06e-05	CbGpPWpGaD
Tamoxifen—CYP3A4—Metabolism—AKR1C3—polycystic ovary syndrome	4.15e-06	2.06e-05	CbGpPWpGaD
Tamoxifen—CYP3A4—Metabolism—CYP17A1—polycystic ovary syndrome	4.09e-06	2.02e-05	CbGpPWpGaD
Tamoxifen—CYP2C19—Metabolism—MTHFR—polycystic ovary syndrome	4.04e-06	2e-05	CbGpPWpGaD
Tamoxifen—CYP1A1—Metabolism—PPARG—polycystic ovary syndrome	4.01e-06	1.98e-05	CbGpPWpGaD
Tamoxifen—CYP2D6—Metabolism—CYP1A1—polycystic ovary syndrome	3.99e-06	1.98e-05	CbGpPWpGaD
Tamoxifen—CYP2C9—Metabolism—CYP1A1—polycystic ovary syndrome	3.95e-06	1.96e-05	CbGpPWpGaD
Tamoxifen—CYP1A1—Metabolism—POMC—polycystic ovary syndrome	3.95e-06	1.96e-05	CbGpPWpGaD
Tamoxifen—ABCB1—Metabolism—MTHFR—polycystic ovary syndrome	3.95e-06	1.95e-05	CbGpPWpGaD
Tamoxifen—CYP1A1—Metabolism—INS—polycystic ovary syndrome	3.93e-06	1.95e-05	CbGpPWpGaD
Tamoxifen—CYP1A2—Metabolism—GNAS—polycystic ovary syndrome	3.74e-06	1.85e-05	CbGpPWpGaD
Tamoxifen—CYP2D6—Metabolism—MTHFR—polycystic ovary syndrome	3.72e-06	1.84e-05	CbGpPWpGaD
Tamoxifen—CYP2C9—Metabolism—MTHFR—polycystic ovary syndrome	3.69e-06	1.83e-05	CbGpPWpGaD
Tamoxifen—CYP2C8—Metabolism—PPARG—polycystic ovary syndrome	3.67e-06	1.82e-05	CbGpPWpGaD
Tamoxifen—CYP2C8—Metabolism—POMC—polycystic ovary syndrome	3.62e-06	1.79e-05	CbGpPWpGaD
Tamoxifen—CYP2C8—Metabolism—INS—polycystic ovary syndrome	3.6e-06	1.78e-05	CbGpPWpGaD
Tamoxifen—CYP1A2—Metabolism—NCOR1—polycystic ovary syndrome	3.56e-06	1.77e-05	CbGpPWpGaD
Tamoxifen—CYP3A4—Metabolism—TH—polycystic ovary syndrome	3.54e-06	1.75e-05	CbGpPWpGaD
Tamoxifen—CYP3A4—Metabolism—SLC2A4—polycystic ovary syndrome	3.44e-06	1.7e-05	CbGpPWpGaD
Tamoxifen—CYP1A2—Metabolism—CYP1A1—polycystic ovary syndrome	3.38e-06	1.67e-05	CbGpPWpGaD
Tamoxifen—CYP2C19—Metabolism—PPARG—polycystic ovary syndrome	3.28e-06	1.62e-05	CbGpPWpGaD
Tamoxifen—CYP3A4—Metabolism—CYP19A1—polycystic ovary syndrome	3.24e-06	1.6e-05	CbGpPWpGaD
Tamoxifen—CYP2C19—Metabolism—POMC—polycystic ovary syndrome	3.23e-06	1.6e-05	CbGpPWpGaD
Tamoxifen—CYP2C19—Metabolism—INS—polycystic ovary syndrome	3.22e-06	1.59e-05	CbGpPWpGaD
Tamoxifen—ABCB1—Metabolism—PPARG—polycystic ovary syndrome	3.2e-06	1.58e-05	CbGpPWpGaD
Tamoxifen—ABCB1—Metabolism—POMC—polycystic ovary syndrome	3.16e-06	1.56e-05	CbGpPWpGaD
Tamoxifen—CYP1A2—Metabolism—MTHFR—polycystic ovary syndrome	3.15e-06	1.56e-05	CbGpPWpGaD
Tamoxifen—ABCB1—Metabolism—INS—polycystic ovary syndrome	3.14e-06	1.55e-05	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—VEGFA—polycystic ovary syndrome	3.13e-06	1.55e-05	CbGpPWpGaD
Tamoxifen—CYP2D6—Metabolism—PPARG—polycystic ovary syndrome	3.02e-06	1.49e-05	CbGpPWpGaD
Tamoxifen—CYP2C9—Metabolism—PPARG—polycystic ovary syndrome	2.99e-06	1.48e-05	CbGpPWpGaD
Tamoxifen—CYP2D6—Metabolism—POMC—polycystic ovary syndrome	2.97e-06	1.47e-05	CbGpPWpGaD
Tamoxifen—CYP2D6—Metabolism—INS—polycystic ovary syndrome	2.96e-06	1.46e-05	CbGpPWpGaD
Tamoxifen—CYP2C9—Metabolism—POMC—polycystic ovary syndrome	2.95e-06	1.46e-05	CbGpPWpGaD
Tamoxifen—CYP2C9—Metabolism—INS—polycystic ovary syndrome	2.93e-06	1.45e-05	CbGpPWpGaD
Tamoxifen—CYP3A4—Metabolism—GNAS—polycystic ovary syndrome	2.89e-06	1.43e-05	CbGpPWpGaD
Tamoxifen—CYP3A4—Metabolism—NCOR1—polycystic ovary syndrome	2.75e-06	1.36e-05	CbGpPWpGaD
Tamoxifen—CYP3A4—Metabolism—CYP1A1—polycystic ovary syndrome	2.61e-06	1.29e-05	CbGpPWpGaD
Tamoxifen—CYP1A2—Metabolism—PPARG—polycystic ovary syndrome	2.55e-06	1.26e-05	CbGpPWpGaD
Tamoxifen—CYP1A2—Metabolism—POMC—polycystic ovary syndrome	2.52e-06	1.25e-05	CbGpPWpGaD
Tamoxifen—CYP1A2—Metabolism—INS—polycystic ovary syndrome	2.51e-06	1.24e-05	CbGpPWpGaD
Tamoxifen—CYP3A4—Metabolism—MTHFR—polycystic ovary syndrome	2.43e-06	1.2e-05	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—IL6—polycystic ovary syndrome	2.17e-06	1.07e-05	CbGpPWpGaD
Tamoxifen—CYP3A4—Metabolism—PPARG—polycystic ovary syndrome	1.97e-06	9.76e-06	CbGpPWpGaD
Tamoxifen—CYP3A4—Metabolism—POMC—polycystic ovary syndrome	1.94e-06	9.63e-06	CbGpPWpGaD
Tamoxifen—CYP3A4—Metabolism—INS—polycystic ovary syndrome	1.93e-06	9.57e-06	CbGpPWpGaD
